Y10S 424/81
Involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Official title: involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Y10S424/81 (Involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy) appears on 270 US grants and 161 published applications in this corpus.
Search patents in Y10S- Granted patents
- 270
- Published applications
- 161
- Assignees
- 172
- Inventors
- 399
- Latest grant
- 11 Sep 2018
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 4 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 6 | 0 |
| 1988 | 5 | 0 |
| 1989 | 0 | 0 |
| 1990 | 3 | 0 |
| 1991 | 4 | 0 |
| 1992 | 6 | 0 |
| 1993 | 11 | 0 |
| 1994 | 6 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 7 | 0 |
| 1998 | 17 | 0 |
| 1999 | 16 | 0 |
| 2000 | 18 | 0 |
| 2001 | 16 | 9 |
| 2002 | 10 | 18 |
| 2003 | 17 | 19 |
| 2004 | 8 | 3 |
| 2005 | 6 | 13 |
| 2006 | 11 | 9 |
| 2007 | 13 | 10 |
| 2008 | 15 | 3 |
| 2009 | 8 | 10 |
| 2010 | 6 | 15 |
| 2011 | 9 | 11 |
| 2012 | 11 | 11 |
| 2013 | 9 | 12 |
| 2014 | 9 | 6 |
| 2015 | 7 | 4 |
| 2016 | 1 | 3 |
| 2017 | 0 | 0 |
| 2018 | 3 | 2 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Method for altering the binding specificity of plasma proteins by oxidation11 Sep 2018US 10,072,068 B2Redox-Reactive Reagents LLC
- Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays10 Jul 2018US 10,018,638 B2Board of Regents, The University of Texas System
- Treatment of pemphigus12 Jun 2018US 9,993,550 B2Biogen Idec Inc.
- IgE CH3 peptide vaccine2 Feb 2016US 9,249,233 B2Pfizer Vaccines LLC
- Method of altering the binding specificity of plasma proteins by oxidation-reduction27 Oct 2015US 9,169,317 B2Redox-Reactive Reagents LLC
- Systems and methods for improved in vivo analyte sensor function22 May 2025US 2025/0160698 A1Abbott Diabetes Care Inc.
- Systems and Methods for Improved In Vivo Analyte Sensor Function2 Jul 2020US 2020/0205706 A1Abbott Diabetes Care Inc.
- Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays7 Feb 2019US 2019/0041399 A1Board of Regents, The University of Texas System
- Treatment of autoimmune diseases20 Sep 2018US 2018/0264107 A1Biogen, Inc.
- Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays15 Feb 2018US 2018/0045736 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Human antibodies that bind human TNFα308US 6,258,562 B1BASF SE · 2001
- Application of botulinum toxin to the management of neurogenic inflammatory disorders270US 6,063,768 A2000
- Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling242US 5,811,097 AThe Regents of the University of California · 1998
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002